Member Info for Dibs61

Must be getting exhausted here at this price

Does anyone think this company will not be moving into serious profit, never mind break even, within the next 24 months given the rapid growth in overseas markets?

Nice report, but what do you actually DO all day every day�?

Impressively strong bounce from this mornings low

Yep a shedload of patience needed here but once the 3D seismic news drops, and assuming its positive, we should get a nice rise here.

Sells coming in way above the mid and quoted bid.

Frits, yep and if STX can do it, and we have an equally (if not more) vital unmet need for Lupus then why wouldn't the FDA give us the nod to go ahead and NDA. If not, we get taken out and a big pharma takes it to market via an additional trial. Far from game over here.

Anyone who believes that Lupuzor is finished following the recent top line results need to read the STX RNS dated 6.4.2018.

The global NIPT market is expected to reach USD 2.88 Billion by 2021 from USD 1.35 Billion in 2016, at a CAGR of 16.4% during the forecast period. Source : https://www.marketsandmarkets.com/PressReleases/non-invasive-prenatal-testing.asp Even if we only grabbed 5% of that market it would be worth �144m sales pa to us. Much of NIPT's focus is to grow our markets in the high growth emerging markets. NIPT current MC : �19m All of which means this is worth a decent punt imo.

Unfortunately its the nature of this bear market we are trying to make money in. Small rises are sold into to grab any profit where it arises. You'll know how difficult it is to make money in this kind of environment. So your company has to have real solid prospects to be rewarded. I believe this is one of a small number of micro caps that does present a real opportunity. So I'm holding and will add on any significant weakness.

Anyone notice STX now up 45% today. Peel Hunt tipped both Shield and IMM as potential takeover targets. Our turn next?

To see the markets now given this a near �14m valuation after recent acquisition. So First Base looks a decent company but they cost FLX �3.2m? Anyone know FB revenue/profits recent history? They have/had some decent clients.

Thanks Falling :D hehe rather happy with our recovery. Up the Palace! Surprised this hasn't dropped more considering the sells today�.

Theres no question Lupuzor is a superior drug to Benlysta given the respective P3 results. Its got better efficacy. FAR better safety profile. Remember what the head of FDA said "If the benefits outweigh the risks"�� Well the benefits clearly DO outweigh the risks. So this will somehow get to market. Its NOT a no hoper. IGNORE the noise. Be patient and wait.

You can fill your boots with as much stock as you like @ 30p atm. My guess is that there's a large order (or orders) being filled around this level. Thats why we're stuck here.

https://www.ft.com/content/cd99b95e-d8ba-11e6-944b-e7eb37a6aa8e Hmmmm I wonder what new technology tool could help labels, publishers and artists plug the �value gap�?. A product which has already been adopted by TWO of the three major record labels already... http://www.tcat.media And who owns 100% of TCAT? Fill your boots boys and girls.

Like I said it matters not whether it�s this update or the next. Litigation resolution key - agreed. I note we have a stealthy buyer(s) in recent times snapping up stock in neat blocks.

You want the evidence? http://www.bbc.co.uk/news/entertainment-arts-43877494 OMIP in this space for sure.

Playoff - you can be sure that MI will NOT raise funds unless there is a very very good reason. Not at all convinced he will as they have already invested very shrewdly to develop TCAT (for example) whilst maintaining profitability in a very challenging environment. That market environment is now improving steadily with the transition to streaming tipping over. Mark my words this is a very well run company indeed. I don�t see many better run companies on AIM. Very confident in this companies future.

I�m not expecting breakeven in the trading update but it matters not imho. It�s inevitably coming sometime within the next year. This isn�t priced for breakeven anyway. It�s suppressed because of the litigation. With the non UK Europe growth so impressive (and not affected by litigation) this looks increasingly attractive at these valuations.